142 related articles for article (PubMed ID: 36806937)
21. Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours.
Flechtner HH; Fischer F; Albers P; Hartmann M; Siener R;
Eur Urol; 2016 Mar; 69(3):518-25. PubMed ID: 26620368
[TBL] [Abstract][Full Text] [Related]
22. Variation in bleomycin hydrolase gene is associated with reduced survival after chemotherapy for testicular germ cell cancer.
de Haas EC; Zwart N; Meijer C; Nuver J; Boezen HM; Suurmeijer AJ; Hoekstra HJ; van der Steege G; Sleijfer DT; Gietema JA
J Clin Oncol; 2008 Apr; 26(11):1817-23. PubMed ID: 18398146
[TBL] [Abstract][Full Text] [Related]
23. A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3).
Shamash J; Sarker SJ; Huddart R; Harland S; Joffe JK; Mazhar D; Birtle A; White J; Chowdhury K; Wilson P; Marshall MR; Vinnicombe S
Ann Oncol; 2017 Jun; 28(6):1333-1338. PubMed ID: 28327896
[TBL] [Abstract][Full Text] [Related]
24. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
[TBL] [Abstract][Full Text] [Related]
25. Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).
Grimison PS; Stockler MR; Chatfield M; Thomson DB; Gebski V; Friedlander M; Boland AL; Houghton B; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong SS; Lewis CR; Vasey PA; Toner GC;
Ann Oncol; 2014 Jan; 25(1):143-8. PubMed ID: 24356625
[TBL] [Abstract][Full Text] [Related]
26. High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA).
Haugnes HS; Laurell A; Stierner U; Bremnes RM; Dahl O; Cavallin-Ståhl E; Cohn-Cedermark G
Acta Oncol; 2012 Feb; 51(2):168-76. PubMed ID: 22175254
[TBL] [Abstract][Full Text] [Related]
27. Longitudinal Changes in Serum Levels of Testosterone and Luteinizing Hormone in Testicular Cancer Patients after Orchiectomy Alone or Bleomycin, Etoposide, and Cisplatin.
Bandak M; Jørgensen N; Juul A; Lauritsen J; Kier MGG; Mortensen MS; Daugaard G
Eur Urol Focus; 2018 Jul; 4(4):591-598. PubMed ID: 28753832
[TBL] [Abstract][Full Text] [Related]
28. Paternity After Treatment for Testicular Germ Cell Cancer: A Danish Nationwide Population-Based Cohort Study.
Bandak M; Jensen A; Dehlendorff C; Lauritsen J; Kreiberg M; Wagner T; Rosenvilde J; Daugaard G
J Natl Cancer Inst; 2022 Jan; 114(1):149-155. PubMed ID: 34180995
[TBL] [Abstract][Full Text] [Related]
29. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
Tandstad T; Dahl O; Cohn-Cedermark G; Cavallin-Stahl E; Stierner U; Solberg A; Langberg C; Bremnes RM; Laurell A; Wijkstrøm H; Klepp O
J Clin Oncol; 2009 May; 27(13):2122-8. PubMed ID: 19307506
[TBL] [Abstract][Full Text] [Related]
30. Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948).
Fosså SD; Paluchowska B; Horwich A; Kaiser G; de Mulder PH; Koriakine O; van Oosterom AT; de Prijck L; Collette L; de Wit R;
Br J Cancer; 2005 Nov; 93(11):1209-14. PubMed ID: 16251877
[TBL] [Abstract][Full Text] [Related]
31. Frequency and risk factors of bleomycin-induced pulmonary toxicity in South Indian patients with germ-cell tumors.
Thakkar DN; Ramasamy K; Adithan S; Selvarajan S; Dubashi B
J Cancer Res Ther; 2021; 17(2):443-449. PubMed ID: 34121690
[TBL] [Abstract][Full Text] [Related]
32. Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection - A 13-year follow-up analysis of a phase III trial cohort.
Hiester A; Fingerhut A; Niegisch G; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Loy V; Wittekind C; Hartmann M; Albers P
Eur J Cancer; 2021 Sep; 155():64-72. PubMed ID: 34371444
[TBL] [Abstract][Full Text] [Related]
33. Sequential trials of cisplatin, vinblastine, and bleomycin and etoposide and cisplatin in disseminated nonseminomatous germ cell tumors of the testis with a good prognosis at a single institution.
Germá JR; Sagarra AF; Izquierdo MA; Seguí MA
Cancer; 1993 Feb; 71(3):796-803. PubMed ID: 7679314
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of non-testicular germ cell tumors in children and adolescents with BEP and VIP: initial results of the MAKEI 89 therapy study].
Göbel U; Bamberg M; Engert J; Gnekow AK; Haas HJ; Jürgens H; Kühl J; Lenard HG; Lumenta C; Niethammer D
Klin Padiatr; 1991; 203(4):236-45. PubMed ID: 1719267
[TBL] [Abstract][Full Text] [Related]
35. Neutrophil-to-lymphocyte ratio in primary mediastinal germ cell tumors: A retrospective analysis of >20 years single institution experience.
Géczi L; Budai B; Polk N; Fazekas F; Bodrogi I; Biró K
Curr Probl Cancer; 2020 Aug; 44(4):100537. PubMed ID: 31980147
[TBL] [Abstract][Full Text] [Related]
36. Survival and toxicity in patients with disseminated germ cell cancer aged 40 years and older.
Thomsen FB; Bandak M; Thomsen MF; Lauritsen J; Christensen IJ; Daugaard G
Cancer; 2014 Jan; 120(1):43-51. PubMed ID: 24108413
[TBL] [Abstract][Full Text] [Related]
37. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council.
de Wit R; Roberts JT; Wilkinson PM; de Mulder PH; Mead GM; Fosså SD; Cook P; de Prijck L; Stenning S; Collette L
J Clin Oncol; 2001 Mar; 19(6):1629-40. PubMed ID: 11250991
[TBL] [Abstract][Full Text] [Related]
38. Second Malignant Neoplasms and Cause of Death in Patients With Germ Cell Cancer: A Danish Nationwide Cohort Study.
Kier MG; Hansen MK; Lauritsen J; Mortensen MS; Bandak M; Agerbaek M; Holm NV; Dalton SO; Andersen KK; Johansen C; Daugaard G
JAMA Oncol; 2016 Dec; 2(12):1624-1627. PubMed ID: 27711914
[TBL] [Abstract][Full Text] [Related]
39. Management of good risk germ-cell tumours.
Troost MM; Sternberg CN; de Wit R
BJU Int; 2009 Nov; 104(9 Pt B):1387-91. PubMed ID: 19840018
[TBL] [Abstract][Full Text] [Related]
40. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.
Culine S; Theodore C; Terrier-Lacombe MJ; Droz JP
J Urol; 1997 Mar; 157(3):855-8; discussion 858-9. PubMed ID: 9072585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
